(MedPage Today) — The Trump administration announced a new demonstration program aimed at easing access to GLP-1 receptor agonists for enrollees in Medicare Part D and Medicaid plans, but experts say it’s unclear how popular or effective it will…
Source link : https://www.medpagetoday.com/publichealthpolicy/washington-watch/119239
Author :
Publish date : 2025-12-31 18:28:00
Copyright for syndicated content belongs to the linked Source.
